KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Total Liabilities (2017 - 2025)

Novartis Ag's Total Liabilities history spans 9 years, with the latest figure at $64.4 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 10.81% year-over-year to $64.4 billion; the TTM value through Dec 2025 reached $64.4 billion, up 10.81%, while the annual FY2025 figure was $64.4 billion, 10.81% up from the prior year.
  • Total Liabilities for Q4 2025 was $64.4 billion at Novartis Ag, up from $58.1 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $64.4 billion in Q4 2025 and bottomed at $53.2 billion in Q4 2023.
  • The 5-year median for Total Liabilities is $58.1 billion (2024), against an average of $59.5 billion.
  • The largest annual shift saw Total Liabilities dropped 10.04% in 2021 before it increased 10.81% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $64.0 billion in 2021, then fell by 9.29% to $58.0 billion in 2022, then dropped by 8.33% to $53.2 billion in 2023, then rose by 9.26% to $58.1 billion in 2024, then grew by 10.81% to $64.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Total Liabilities are $64.4 billion (Q4 2025), $58.1 billion (Q4 2024), and $53.2 billion (Q4 2023).